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Aim: To identify, predict and validate distinct glycaemic trajectories among patients with newly
diagnosed type 2 diabetes treated in primary care, as a first step towards more effective
patient-centred care.
Methods: We conducted a retrospective study in two cohorts, using routinely collected individ-
ual patient data from primary care practices obtained from two large Dutch diabetes patient
registries. Participants included adult patients newly diagnosed with type 2 diabetes between
January 2006 and December 2014 (development cohort, n = 10 528; validation cohort,
n = 3777). Latent growth mixture modelling identified distinct glycaemic 5-year trajectories.
Machine learning models were built to predict the trajectories using easily obtainable patient
characteristics in daily clinical practice.
Results: Three different glycaemic trajectories were identified: (1) stable, adequate glycaemic
control (76.5% of patients); (2) improved glycaemic control (21.3% of patients); and (3) deterio-
rated glycaemic control (2.2% of patients). Similar trajectories could be discerned in the valida-
tion cohort. Body mass index and glycated haemoglobin and triglyceride levels were the most
important predictors of trajectory membership. The predictive model, trained on the develop-
ment cohort, had a receiver-operating characteristic area under the curve of 0.96 in the valida-
tion cohort, indicating excellent accuracy.
Conclusions: The developed model can effectively explain heterogeneity in future glycaemic
response of patients with type 2 diabetes. It can therefore be used in clinical practice as a quick
and easy tool to provide tailored diabetes care.
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1 | INTRODUCTION
Archibold Garrod is considered the founding father of precision medi-
cine. In 1931, he was the first to recognize interpersonal variation in
disease development and impact. Garrod noted that “individual cases
of any particular disease are not exactly alike; they resemble rather
the drawings made from the same model by individual members of a
drawing class.”1 Nowadays, precision medicine is becoming more
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popular because of an increase in electronic clinical data and a decline
in genome sequencing costs.2,3 In 2012, former UK Prime Minister
David Cameron initiated the 100 000 Genomes Project and in 2015
former US president Barack Obama launched the Precision Medicine
Initiative.4,5 The aim of both initiatives was to predict the process of
disease and to create personalized patient care by gaining more
knowledge on genetic variation in disease.
Significant advances have been made thus far, such as the dis-
covery of certain genetic variations that are linked to the effective-
ness of a drug or specific genes that predict cancer risk.6,7
Nevertheless, the implementation of precision medicine based
solely on genomics has proven to be difficult for certain diseases,
such as type 2 diabetes. Recently, new efforts have been under-
taken to unravel the genetic background of type 2 diabetes by
studying not only common gene variants, but also infrequent and
rare variants.8 To date, only 10% of its heritability has been
unveiled, which has been referred to as a “geneticist's nightmare”
by some experts.9 Consequently, precision medicine based on a
genotyping approach is still far away for type 2 diabetes. Shifting to
a phenotyping approach of precision medicine seems a more prom-
ising alternative, in particular in the short-term, to improve patients'
health outcomes.10,11 The US National Institutes of Health defines
precision medicine as an emerging approach for disease treatment
and prevention that takes into account not only individual variability
in genes, but also a patient's environment and lifestyle.12 Currently,
such a phenotyping approach to precision medicine is only sparsely
adopted in evidence-based guidelines for diabetes treatment. Bar-
ring some exceptions for older people, these guidelines are usually
highly standardized.13,14
As a first step towards more patient-centred care, the aim of the
present study was 3-fold. It aimed: (1) to identify subgroups of people
with newly diagnosed type 2 diabetes with distinct glycaemic trajec-
tories; (2) to predict trajectory membership using patient characteris-
tics that are commonly assessed in diabetes primary care; and (3) to
validate these findings in a different cohort of patients with type
2 diabetes.
2 | RESEARCH DESIGN AND METHODS
2.1 | Study design and patients
In this retrospective cohort study, patients were selected using the
electronic health records (EHRs) of two large Dutch diabetes care
networks (DCNs) that routinely collect individual patient data and
have been frequently used for research.15–19 General practitioners
and practice nurses from the participating practices recorded these
data in the EHRs from the start of diabetes diagnosis. They use the
information in the EHRs for the treatment and follow-up of their
patients and as proof that they provided the care as agreed upon
with health insurers for declaration purposes; therefore, it can be
considered accurate. Patients from both DCNs received managed dia-
betes primary care based on the Netherlands Diabetes Federation
Care Standard,13 which describes the norm for generic multidisciplin-
ary diabetes care.
The first DCN, the Zwolle Outpatient Diabetes project Inte-
grating Available Care (ZODIAC),20 was used for the development
cohort and contained the anonymous longitudinal health records of
93 981 adult patients (age ≥ 18 years) with type 2 diabetes from
731 primary care practices in the city of Rotterdam, and in north-
ern, north-western and eastern parts of the Netherlands. The data
in the present study were collected during the yearly visits
between January 1, 2006 and December 31, 2013. Those patients
with a new diagnosis of type 2 diabetes during the study period
and with at least one glycated haemoglobin (HbA1c) value, mea-
sured 3 months from diagnosis (baseline), were selected for fur-
ther analysis.
The second DCN, the regional care group ZIO,18 was used as the
validation cohort. The ZIO database contains the anonymous longitu-
dinal health records of 11 833 adult patients (age ≥ 18 years) with
type 2 diabetes from 95 primary care practices in Maastricht, in the
south of the Netherlands. Data were collected and registered in the
EHRs between January 1, 2009 and December 31, 2014. The inclu-
sion criteria were the same as for the development cohort.
Both cohorts were open and dynamic, and patients were fol-
lowed from diagnosis until the end of the study period or until cen-
soring because no more HbA1c measurements were available
(because of death, no show or change of practice). Patients' date of
entry into the study (baseline) was fixed at their registered date of
diagnosis of type 2 diabetes.
No ethical approval was needed for the study; as the data used
were already available and patients were not physically involved in
the research, the study was not subject to the Dutch Medical
Research (Human Subjects) Act.
2.2 | Outcome
The outcome of interest was glycaemic control trajectories, based on
HbA1c values during a maximum of 4 years (development cohort) or
5 years (validation cohort). Baseline HbA1c values were included if
measured 3 months from diagnosis. Follow-up HbA1c values were
included if measured 1 year from the previous HbA1c measurement
with a deviation of 3 months.
2.3 | Predictors
The baseline patients' characteristics were used as potential predic-
tors for an individual's glycaemic trajectory membership. Characteris-
tics included baseline age, sex, and race, which was categorized into a
binary variable of white or non-white because participants were
mainly white. Non-white included Moroccan, Turkish, black-African,
Indian, Indonesian and non-Indian in the development cohort, and
black, Indian and other Asian in the validation cohort. HbA1c, systolic
blood pressure (SBP), diastolic blood pressure (DBP), lipid profile (LDL
cholesterol, HDL cholesterol, total cholesterol and triglycerides), and
body mass index (BMI) were also included as baseline characteristics
if measured 3 months from diagnosis. Urinary albumin-to-creatinine
ratio (ACR), presence of heart failure (only reported in the develop-
ment cohort), smoking (yes/no) and alcohol consumption (≤3 glas-
ses/d or >3 glasses/d) were included as baseline characteristics if
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measured 12 months from diagnosis. Patient-reported history of
cardiovascular disease (CVD) in family members aged <60 years
(yes/no) was included in the analysis if obtained at any point before
diagnosis or a maximum 12 months after diagnosis.
Outliers, most likely attributable to errors in recording, were
removed based on cut-off points determined by diabetologists
(Martijn Brouwers and Nicolaas Schaper).
2.4 | Statistical methods
To identify systematically the latent trajectories of glycaemic control,
latent growth mixture modelling (LGMM) was used. This method
allows the clustering of patients into an optimal number of growth tra-
jectories.21 Full information maximum likelihood was used as a missing
data estimation approach.22 A protocol, as recommended
previously,23,24 was followed to identify the best LGMM model. A
series of latent class growth analysis and latent growth mixture models
were estimated. Latent class growth analysis assumes no within class
variance, whereas LGMM freely estimates the within-class variance.23
The best model was determined by comparing the model fits of a pro-
gressive number of trajectories. Fit indices included the Akaike Infor-
mation Criterion,25 Bayesian Information Criterion26 and the Lo-
Mendel-Rubin-likelihood ratio test.27 Lower values of Akaike Informa-
tion Criterion and Bayesian Information Criterion, and/or a significant
result on the the Lo-Mendel-Rubin-likelihood ratio test indicate a bet-
ter model fit in terms of the number of trajectories. To determine
model classification performance, entropy was used. Higher entropy
values indicate less ambiguity in trajectory allocation.28 The usefulness
and clinical interpretation of each trajectory model was also taken into
account. Analyses were performed using Mplus version 7.1.29 and are
reported according to the Guidelines for Reporting on Latent Trajec-
tory Studies (GRoLTS) checklist.24 Baseline characteristics were
assessed for the development and validation cohorts. Significant dif-
ferences between cohorts were determined using two-sample t-tests
and chi-squared tests. ANOVA and χ2 tests were used to identify sig-
nificant differences between glycaemic control trajectories within
each cohort. To gain insight into the influence of glucose-lowering
drugs and insulin on the patterns of the trajectories, the percentage of
patients with oral glucose-lowering drugs and/or insulin prescriptions
was compared at baseline and at each follow-up year between the tra-
jectories of the development cohort using chi-squared tests.
For the development and validation of the prediction model, only
patients with no missing baseline values were included. A 5-fold
cross-validation was performed in the development cohort. Because
there is no consensus on the best-performing classifier, several
machine learning classification methods were used.30 The correlations
between SBP and DBP, lipid profile characteristics and CVD charac-
teristics were calculated using the Spearman (for non-normally dis-
tributed variables) and Pearson (for normally distributed variables)
correlation coefficients. If there was a significant correlation coeffi-
cient ≤−0.4 or ≥0.4 between two potential predictors, only one
potential predictor was included in the analysis to avoid over-adjust-
ment. To examine the generalizability of the developed prediction
model, an external validation was computed in the validation cohort.
Receiver-operating characteristic (ROC) curves were generated to
show the discrimination of the models. To examine the agreement
between predicted and observed trajectory membership, calibration
slopes were produced. Diagnostic values (sensitivities and specific-
ities) and prognostic values (positive predictive values [PPVs] and
negative predictive values [NPVs]) were also calculated.
For further details regarding the analyses see File S1.
3 | RESULTS
3.1 | Development and validation cohorts
The initial development cohort included 20 414 patients who were
diagnosed with type 2 diabetes between January 1, 2006 and
December 31, 2013. Of these, 10 528 patients had a baseline HbA1c
measurement and were included in the analysis. The group of patients
without a baseline HbA1c measurement had significantly higher LDL
cholesterol levels (3.0 vs 2.9 mmol/L, 95% confidence interval
[CI] 0.05–0.14; P < .001) and included a lower percentage of women
(46.9% vs 48.4%, 95% CI 0.2–3.0; P = .031). Other characteristics did
not differ. The mean (SD) age of the included patients in the develop-
ment cohort was 62.9 (12.7) years and 51.6% were men (Table 1).
The initial validation cohort included 4164 patients who were
diagnosed with type 2 diabetes between January 1, 2009 and
December 31, 2014. Of these, 3337 adult patients had a baseline
HbA1c measurement and were therefore selected for inclusion in the
analysis. The group of patients without a baseline HbA1c measure-
ment was significantly older (64.9 vs 63.7 years, 95% CI 0.3–2.1,
P = .009) and had a lower percentage of CVD in the family (19% vs
24.2%, 95% CI 1.4–8.0; P = .008). Other characteristics did not differ.
The mean (SD) age of the included patients in the validation cohort
was 63.7 (12.2) years and 52.3% were men (Table 1).
In both the development and validation cohort, date of diagnosis
(and inclusion into the study) differed considerably between patients:
some patients were, for example, diagnosed in 2009 and others in
2013, resulting in a variable follow-up. Because of this variable
follow-up, 78.7% of the patients in the development cohort did not
have an HbA1c measurement after 4 years of follow-up and 72.9%
did not have an HbA1c measurement after 5 years of follow-up in
the validation cohort (Table S1). It was therefore decided to restrict
follow-up in the development cohort to 4 years and in the validation
cohort to 5 years. The median (interquartile range) number of HbA1c
measurements during the research period was 2 (2) in the develop-
ment cohort and 3 (3) in the validation cohort.
3.2 | Latent growth mixture modelling
The model with the strongest fit in the development cohort was the
3-trajectory LGMM (Table S2). The largest (76.5%) and most stable
trajectory showed a pattern of good glycaemic control (HbA1c ≤7%
[53 mmol/mol]) over time (Figure 1). This trajectory was named “sta-
ble, adequate glycaemic control.” The middle trajectory, including
21.3% of the population, was named “improved glycaemic control,”
because patients in this trajectory adequately responded to glycaemic
treatment and subsequently remained stable at a HbA1c level just
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TABLE 1 Baseline patient characteristics of the development cohort and the validation cohort
Development cohort Validation cohort P
N 10 528 3337
Mean (SD) age, years 62.9 (12.7) 63.7 (12.2) .001
Not recorded, n 0 0
Men, n (%) 5433 (51.6) 1744 (52.3) <.001
Not recorded 0 0
Ethnic groupa, n (%) .797
White 6669 (95.3) 2913 (95.5)
Non-white 330 (4.7) 137 (4.5)
Not recorded 3529 287
Smoking statusa, n (%) <.001
Non-smoker 7748 (80.1) 2065 (74.8)
Current smoker 1928 (19.9) 695 (25.2)
Not recorded 852 577
Mean (SD) BMI, kg/m2 30.4 (5.5) 30.6 (6.1) .073
Not recorded, n 4443 595
Alcohol consumptiona, n (%) .308
<3 glasses/d 6029 (76.3) 3147 (94.6)
≥3 glasses/d 1876 (23.7) 178 (5.4)
Not recorded 2623 12
Mean (SD) HbA1c, mmol/mol 53.0 (15.3) 56.9 (18.8) <.0001
Not recorded, n 0 0
Mean (SD) HbA1c, % 7.0 (1.4) 7.4 (1.7) <.0001
Not recorded, n 0 0
Mean (SD) SBP, mm Hg 138.5 (17.6) 138.4 (18.8) .321
Not recorded, n 3762 483
Mean (SD) DBP, mm Hg 80.8 (10.0) 80.8 (10.4) .801
Not recorded, n 4014 489
Mean (SD) LDL cholesterol, mmol/mol 2.9 (1.0) 3.2 (1.1) .954
Not recorded, n 1910 663
Mean (SD) HDL cholesterol, mmol/mol 1.23 (0.4) 1.16 (0.35) <.001
Not recorded, n 1536 638
Mean (SD) total cholesterol, mmol/mol 5.0 (1.1) 5.3 (1.3) <.001
Not recorded, n 1500 628
Mean (SD) triglycerides, mmol/L 2.0 (1.2) 2.2 (1.4) <.001
Not recorded, n 1809 659
Mean (SD) ACR, mg/mmol 2.7 (9.9) 2.3 (9.8) .002
Not recorded, n 2717 812
Mean (SD) eGFR, ml/min/1.73m2 80.1 (21.6) 77.7 (24.0) .005
Not recorded 9620 454




CVD in familya, n (%) 0.018
Yes 2718 (37.9) 810 (24.3)
No 4457 (62.1) 2521 (75.7)
Not recorded 3353 6
Abbreviations: ACR, albumin-to-creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glo-
merular filtration rate; HbA1c, glycated haemoglobin; SBP, systolic blood pressure. Percentages have been rounded and might not total 100.
a Percentages are out of total with recorded values.
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above 7% (53 mmol/mol). The smallest trajectory (2.2%) showed very
high HbA1c at diagnosis of diabetes, but adequately responded to
treatment; however, 2 years after diagnosis, HbA1c started to
increase again to levels >7% (53 mmol/mol). This trajectory was
named “deteriorated glycaemic control.” The mean intercepts and
slopes for each class are presented in Table S3. All intercepts and
slope growth parameters were statistically significant. The observed
individual trajectories and estimated mean trajectory of the three-
trajectory model are shown in Figure S1.
In the validation cohort, a three-trajectory model was also identi-
fied based on model fit (Table S4) and population trajectory distribu-
tion (Figure 1). This model was similar in shape and population
distribution to the three-trajectory model of the development cohort.
All intercepts and slope growth parameters were statistically signifi-
cant (Table S3).
Figures S1–S5 show all fitted trajectory models in the develop-
ment and validation cohorts with linear and quadratic slopes, in
accordance with the GRoLTS guidelines.24
There were significant differences between trajectories at all time
points in the percentages of patients with oral glucose-lowering drugs
and insulin prescriptions (P < .0001). Figures S6 and S7 show that more
oral glucose-lowering drugs and insulin were prescribed to patients in
the deteriorated and improved glycaemic control trajectories compared
with the stable, adequate glycaemic control trajectory. Prescription of
oral glucose-lowering drugs increased over time in all trajectories.
3.3 | Classification into glycaemic control
trajectories
In both cohorts, patients in the deteriorated glycaemic control trajec-
tory were more frequently male, current smokers and younger. Their
baseline HbA1c, triglycerides and total cholesterol levels were higher
compared with the other trajectories (Table 2).
After excluding significant correlations between patient charac-
teristics (Table S5), 13 baseline characteristics were retained in the
analyses as potential predictors: age; gender; race; HbA1c; SBP; LDL
cholesterol; triglycerides; ACR; BMI; smoking; alcohol; CVD; and CVD
in family members. The 5-fold cross-validation in the development
cohort showed that the K-nearest neighbour machine learning classi-
fier had the highest accuracy (92.3%; Table S6). Using this classifier,
the 13-patient feature prediction model had good-to-excellent diag-
nostic and prognostic properties, with sensitivities between 78.4%
and 98.3%, specificities between 81.2% and 99.4%, PPVs between
78.0% and 94.7% and NPVs between 93.7% and 99.5% (Table S7).
Baseline BMI, HbA1c and triglycerides were the most salient charac-
teristics for predicting trajectory membership according to their
weight (Table 3). The 13-patient feature prediction model had a ROC-
AUC of 0.95 (Figure 2). The external validity of the model with the
three most salient patient characteristics (3-patient feature prediction
model) was determined in the validation cohort. The linear discrimi-
nant classifier had the highest accuracy (92.0%; Table S8). Sensitivities
were between 67.9% and 99.1%, specificities between 85.3% and
98.6%, PPVs between 45.8 and 96.1% and NPVs between 91.9% and
99.4% (Table S9). The ROC-AUC was 0.96 (Figure 2). The calibration
plot in the validation cohort showed a good fit for all three trajectories
(Figure S8). The developed tool can be found on the webpage www.
patientprofiles.nl and provides the opportunity to fill in different BMI,
HbA1c and triglyceride values and to view the related trajectory.
4 | DISCUSSION
In the present retrospective cohort study in patients with newly diag-
nosed type 2 diabetes treated in primary care, three distinct glycaemic
trajectories were identified during the first 5 years after diagnosis:
(1) stable, adequate glycaemic control; (2) improved glycaemic control;
and (3) deteriorated glycaemic control. Our most important finding
was that trajectory membership can be predicted with good-to-
excellent accuracy using no more than three patient characteristics
(baseline BMI, HbA1c and triglycerides). The generalizability of the
model, obtained by training the model on the development cohort and
testing it on the validation cohort, was also excellent.
FIGURE 1 Latent class growth trajectories of the best-fitting models of the development and validation cohorts identified by latent growth
mixture modelling. Solid lines = development cohort; dashed lines = validation cohort
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To our knowledge, only two previous studies have examined
latent glycaemic trajectories in patients with type 2 diabetes.31,32
Both studies identified four glycaemic trajectories, which had notable
similarities to the trajectory patterns we observed in the present
study. The similarities between the previous and present studies were
most notable for the “stable, adequate glycaemic control” trajectory.
In both previous studies, this trajectory was identified and included
83% of their patients, slightly higher than the 72% we found. These
results indicate that current practice enables a majority of patients to
reach and maintain recommended glycaemic control levels. The pre-
sent study shows that this group of patients can be identified at diag-
nosis by applying a model that has a high PPV and NPV.
These findings have important implications for more precision
medicine in type 2 diabetes. The main goal of precision medicine is to
develop models that can predict disease development or disease
outcomes in order to tailor treatment.3 Our model uses three rela-
tively simple clinical characteristics, BMI, HbA1c and triglycerides, to
divide patients into three groups, each with different future glycaemic
trajectories. Predicting patients' future glycaemic control enables care
professionals to provide tailored diabetes management. For patients
classified in the stable, adequate glycaemic control group, for example,
less intensive monitoring might suffice, whereas patients classified in
the deteriorated glycaemic control group could benefit more from fre-
quent monitoring. Previous research suggests that less frequent moni-
toring of patients with stable, adequate glycaemic control – that is,
biannual instead of quarterly check-ups by a general practitioner – is
possible without negative effects on health, allowing considerable
cost reductions.33 More generally, our model enables tailoring of a
range of diabetes care components to patients' care needs, including
pharmacotherapy, lifestyle advice and self-management support.
TABLE 2 Baseline characteristics of the development cohort and the validation cohort according to the different trajectories of HbA1c

















N (%) 8049 (76.5) 2246 (21.3) 233 (2.2) 2516 (75.4) 702 (21.0) 119 (3.6)
Mean (SD) age, years 63.8 (12.3) 60.3 (13.6) 59.3 (12.6) <.001 64.9 (11.6) 60.3 (13.5) 59.7 (12.2) <.001
Men, n (%) 4026 (50.0) 1261 (56.1) 146 (62.7) <.001 1249 (49.6) 417 (59.4) 78 (65.5) <.001
Ethnic groupa, n (%) .013 .797
White 5116 (95.7) 1415 (94.0) 138 (93.2) 2185 (95.4) 623 (96) 105 (95.5)
Non-white 230 (4.3) 90 (6.0) 10 (6.8) 106 (4.6) 26 (4.0) 5 (4.5)
Smoking statusa, n (%) <.001 <.001
Non-smoker 6008 (80.9) 1595 (77.8) 145 (71.8) 1585 (76.9) 415 (69.5) 65 (64.4)
Current smoker 1416 (19.1) 455 (22.2) 57 (28.2) 477 (23.1) 182 (30.5) 36 (35.6)
Mean (SD) BMI, kg/m2 30.3 (5.3) 30.8 (6.1) 29.2 (4.8) .103 30.4 (6.1) 31.0 (5.7) 31.1 (6.3) .073
Alcohol consumptiona, n (%) .553 .308
<3 glasses/d 4595 (76.0) 1301 (76.9) 133 (78.7) 2375 (94.8) 664 (94.7) 108 (91.5)
≥3 glasses/d 1450 (24.0) 390 (23.1) 36 (21.3) 131 (5.2) 37 (5.3) 10 (8.5)
Mean (SD) HbA1c, mmol/mol 46.5 (5.7) 70.3 (14.1) 107.2 (15.2) <.001 48.4 (5.8) 78.0 (16.9) 112.5 (16.7) <.001
Mean (SD) HbA1c, % 6.4 (0.5) 8.6 (1.3) 11.9 (1.4) <.001 6.6 (0.5) 9.3 (1.5) 12.5 (1.5) <.001
Mean (SD) SBP, mm Hg 138.5 (17.3) 138.8 (18.5) 137.2 (17.7) .460 138.2 (18.7) 139.8 (19.2) 135.3 (17.4) .321
Mean (SD) DBP, mm Hg 80.5 (9.8) 81.7 (10.6) 82.3 (10.3) .003 80.3 (10.5) 82.6 (10.3) 81.7 (9.8) .238
Mean (SD) LDL cholesterol,
mmol/mol
2.9 (1.0) 3.0 (1.0) 3.3 (1.0) <.001 3.2 (1.1) 3.3 (1.1) 3.5 (1.2) .954
Mean (SD) HDL cholesterol,
mmol/mol
1.3 (0.4) 1.1 (0.3) 1.2 (0.3) <.001 1.2 (0.4) 1.0 (0.3) 1.1 (0.3) <.001
Mean (SD) total cholesterol,
mmol/mol
4.9 (1.1) 5.1 (1.3) 5.4 (1.2) <.001 5.3 (1.2) 5.4 (1.3) 5.9 (1.7) .003
Mean (SD) triglycerides,
mmol/L
1.9 (1.1) 2.2 (1.4) 2.4 (1.8) <.001 2.1 (1.2) 2.6 (1.6) 3.6 (2.9) <.001
Mean (SD) ACR,
mg/mmol
2.4 (9.2) 3.8 (12.2) 3.4 (8.4) <.001 2.2 (10.3) 2.3 (7.1) 3.7 (12.5) .002
Heart failurea, n (%) .901 - - - -
Yes 337 (6.7) 92 (6.5) 8 (5.9)
No 4697 (93.3) 1328 (93.5) 128 (94.1)
CVD in familya, n (%) .534 .018
Yes 2072 (37.8) 591 (38.6) 55 (34.2) 603 (24.0) 189 (27.0) 18 (15.3)
No 3409 (62.2) 942 (61.4) 106 (65.8) 1909 (76.0) 512 (73.0) 100 (84.7)
Abbreviations: ACR, albumin-to-creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; HbA1c, glycated hae-
moglobin; SBP, systolic blood pressure. Percentages have been rounded and might not total 100.
a Percentages are out of total with recorded values.
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In the present study we applied a unique approach by combining
LGMM with machine learning techniques. There were three follow-
up HbA1c measurements in the development cohort and four in the
validation cohort, allowing the identification of heterogeneity in
future glycaemic response. Prescription of glucose-lowering drugs
and insulin may have influenced the patterns of the trajectories.
HbA1c levels in the stable, adequate and improved glycaemic control
trajectories remained stable or improved, possibly because of an
increase in oral and insulin prescriptions over time. In the deterio-
rated glycaemic control trajectory, however, HbA1c increased,
despite an increase in glucose-lowering drugs and insulin prescrip-
tions. Disease progression or difficulties adhering to drug treatment
and healthy lifestyle could be explanations for this.34,35
The external validation is an important strength of the present
study, considering that many research findings are based solely on
the basis of a single study.36 A limitation was that both cohorts
consisted of a predominantly white population. When compared with
white populations, other races tend to have higher HbA1c values,37
and their inclusion might have resulted in glycaemic control trajecto-
ries that differed in size and shape. One of the previous studies that
examined latent glycaemic control trajectories31 included a mixed-
race population, with ~50% non-white participants; however, as
stated before, the identified trajectories in that study were similar to
the trajectories in the present study.
So far, predictive models and tools based on machine learning
techniques have not been widely used in clinical decision support
systems.38 One of the reasons for this could be that data obtained
from EHRs are considered a byproduct of healthcare delivery, rather
than a resource to improve its performance.39 In addition, most
machine learning models are complex and difficult to interpret
because they depend heavily on aspects related to feature distribu-
tion, data availability and data representation.40 In the present study
we built and validated a simple and interpretable algorithm with
excellent accuracy. Despite the high PPV and NPV in the stable, ade-
quate glycaemic control trajectory, the PPV in the deteriorated gly-
caemic control trajectory was only 45.8% in the validation cohort.
This implies that more than half the patients classified in this trajec-
tory do not belong there (false-positives), which is a point for further
refinement. The counterpart is that the NPV is high, implying that
membership of this trajectory can be ruled out with high certainty.
In conclusion, only three patient characteristics (BMI, HbA1c and
triglycerides) are needed to accurately predict glycaemic response of
patients with newly diagnosed type 2 diabetes. The model can be
used in practice as a quick, easy and accurate tool to determine
patients' care needs and provide tailored diabetes treatment.
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TABLE 3 Patient feature ranking of the 5-fold cross-validation as
observed in the development cohort









9 Alcohol consumption 0.0142
10 Smoking 0.0142
11 CVD in family 0.0142
12 Heart failure 0.0142
13 Race 0.0142
Abbreviations: ACR, albumin-to-creatinine ratio; BMI, body mass index;
CVD, cardiovascular disease; HbA1c, glycated haemoglobin; SBP, systolic
blood pressure.
FIGURE 2 Receiver-operating characteristic curve of the 13-patient
feature prediction model and the 3-patient feature prediction model.
TP, true-positive; FP, false-positive; KNN, K-nearest neighbour; LDC,
linear discriminant classifier
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